A Pilot Study to Assess Safety and Biomarker Responses of the Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Brepocitinib (Primary)
- Indications Alopecia
- Focus Adverse reactions; Pharmacodynamics
- 06 Oct 2023 Status changed from active, no longer recruiting to completed.
- 02 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2022 Planned End Date changed from 1 Dec 2023 to 1 Sep 2023.